Pinnacle Associates LTD Cytokinetics Inc Transaction History

Pinnacle Associates LTD

$6.3 Billion
Q3 2024

A detailed history of Pinnacle Associates LTD transactions in Cytokinetics Inc stock. As of the latest transaction made, Pinnacle Associates LTD holds 258,358 shares of CYTK stock, worth $12.7 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

258,358

Previous 253,864 1.77%

Holding current value

$12.7 Million

Previous $13.8 Million 0.82%

% of portfolio

0.22%

Previous 0.22%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 25, 2024	BUY	$51.22 - $60.16 $230,182 - $270,359	4,494 Added 1.77%	258,358 $13.6 Million
Q2 2024 Jul 30, 2024	SELL	$47.86 - $75.05 $158,081 - $247,890	-3,303 Reduced 1.28%	253,864 $13.8 Million
Q1 2024 Apr 26, 2024	SELL	$63.75 - $108.06 $75,926 - $128,699	-1,191 Reduced 0.46%	257,167 $18 Million
Q4 2023 Jan 19, 2024	SELL	$26.88 - $83.49 $26,100 - $81,068	-971 Reduced 0.37%	258,358 $21.6 Million
Q3 2023 Oct 23, 2023	SELL	$29.46 - $36.61 $325,002 - $403,881	-11,032 Reduced 4.08%	259,329 $7.64 Million
Q2 2023 Jul 26, 2023	SELL	$32.62 - $40.75 $314,619 - $393,033	-9,645 Reduced 3.44%	270,361 $8.82 Million
Q1 2023 May 04, 2023	SELL	$33.36 - $45.71 $158,093 - $216,619	-4,739 Reduced 1.66%	280,006 $9.85 Million
Q4 2022 Jan 31, 2023	BUY	$35.77 - $51.11 $24,466 - $34,959	684 Added 0.24%	284,745 $13 Million
Q4 2022 Jan 25, 2023	SELL	$35.77 - $51.11 $207,108 - $295,926	-5,790 Reduced 2.0%	284,061 $0
Q3 2022 Oct 31, 2022	SELL	$38.54 - $54.52 $396,769 - $561,283	-10,295 Reduced 3.43%	289,851 $14 Million
Q2 2022 Aug 02, 2022	SELL	$33.93 - $48.92 $44,719 - $64,476	-1,318 Reduced 0.44%	300,146 $11.8 Million
Q1 2022 May 05, 2022	SELL	$29.74 - $46.0 $408,270 - $631,488	-13,728 Reduced 4.36%	301,464 $11.1 Million
Q4 2021 Feb 02, 2022	SELL	$34.35 - $46.38 $69,490 - $93,826	-2,023 Reduced 0.64%	315,192 $14.4 Million
Q3 2021 Oct 19, 2021	SELL	$18.54 - $35.74 $225,817 - $435,313	-12,180 Reduced 3.7%	317,215 $11.3 Million
Q2 2021 Aug 02, 2021	BUY	$19.79 - $26.99 $100,849 - $137,541	5,096 Added 1.57%	329,395 $6.52 Million
Q1 2021 May 12, 2021	SELL	$18.57 - $25.68 $657,842 - $909,714	-35,425 Reduced 9.85%	324,299 $7.54 Million
Q4 2020 Jan 26, 2021	SELL	$15.26 - $28.61 $371,382 - $696,281	-24,337 Reduced 6.34%	359,724 $7.48 Million
Q3 2020 Oct 23, 2020	SELL	$20.58 - $28.96 $311,107 - $437,788	-15,117 Reduced 3.79%	384,061 $8.32 Million
Q2 2020 Aug 14, 2020	SELL	$11.15 - $24.64 $41,422 - $91,537	-3,715 Reduced 0.92%	399,178 $9.41 Million
Q1 2020 May 13, 2020	SELL	$8.75 - $16.3 $626,351 - $1.17 Million	-71,583 Reduced 15.09%	402,893 $4.75 Million
Q4 2019 Feb 03, 2020	SELL	$7.95 - $11.84 $358,505 - $533,924	-45,095 Reduced 8.68%	474,476 $5.03 Million
Q3 2019 Nov 08, 2019	SELL	$10.82 - $14.25 $292,951 - $385,818	-27,075 Reduced 4.95%	519,571 $5.91 Million
Q2 2019 Aug 05, 2019	SELL	$7.95 - $11.25 $427,248 - $604,597	-53,742 Reduced 8.95%	546,646 $6.15 Million
Q1 2019 May 10, 2019	BUY	$5.95 - $10.19 $45,279 - $77,545	7,610 Added 1.28%	600,388 $4.86 Million
Q4 2018 Feb 05, 2019	SELL	$5.91 - $9.29 $333,991 - $525,005	-56,513 Reduced 8.7%	592,778 $3.75 Million
Q3 2018 Nov 13, 2018	SELL	$6.4 - $9.85 $697,817 - $1.07 Million	-109,034 Reduced 14.38%	649,291 $6.4 Million
Q2 2018 Aug 08, 2018	SELL	$6.9 - $9.9 $897,621 - $1.29 Million	-130,090 Reduced 14.64%	758,325 $6.29 Million
Q1 2018 May 11, 2018	BUY	$7.2 - $10.05 $78,048 - $108,942	10,840 Added 1.24%	888,415 $6.4 Million
Q4 2017 Feb 12, 2018	SELL	$7.25 - $15.65 $951,417 - $2.05 Million	-131,230 Reduced 13.01%	877,575 $7.15 Million
Q3 2017 Nov 13, 2017	BUY	$12.0 - $15.0 $12.1 Million - $15.1 Million	1,008,805	1,008,805 $14.6 Million

Others Institutions Holding CYTK

# of Institutions

410

Shares Held

125M

Call Options Held

4.6M

Put Options Held

2.43M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.62B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.

Account

Pinnacle Associates LTD Cytokinetics Inc Transaction History